These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 32284379)

  • 41. Skin muscle is the initial site of viral replication for arboviral bunyavirus infection.
    Schneider CA; Leung JM; Valenzuela-Leon PC; Golviznina NA; Toso EA; Bosnakovski D; Kyba M; Calvo E; Peterson KE
    Nat Commun; 2024 Feb; 15(1):1121. PubMed ID: 38321047
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Innate immune response to La Crosse virus infection.
    Taylor KG; Peterson KE
    J Neurovirol; 2014 Apr; 20(2):150-6. PubMed ID: 23846288
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of La Crosse virus infection on pregnant domestic rabbits and mongolian gerbils.
    Osorio JE; Schoepp RJ; Yuill TM
    Am J Trop Med Hyg; 1996 Oct; 55(4):384-90. PubMed ID: 8916793
    [TBL] [Abstract][Full Text] [Related]  

  • 44. La Crosse Virus Neuroinvasive Disease in Children: A Contemporary Analysis of Clinical/Neurobehavioral Outcomes and Predictors of Disease Severity.
    Boutzoukas AE; Freedman DA; Koterba C; Hunt GW; Mack K; Cass J; Yildiz VO; de Los Reyes E; Twanow J; Chung MG; Ouellette CP
    Clin Infect Dis; 2023 Feb; 76(3):e1114-e1122. PubMed ID: 35607778
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interferon-induced rat Mx proteins confer resistance to Rift Valley fever virus and other arthropod-borne viruses.
    Sandrock M; Frese M; Haller O; Kochs G
    J Interferon Cytokine Res; 2001 Sep; 21(9):663-8. PubMed ID: 11576460
    [TBL] [Abstract][Full Text] [Related]  

  • 46. La Crosse virus nonstructural protein NSs counteracts the effects of short interfering RNA.
    Soldan SS; Plassmeyer ML; Matukonis MK; González-Scarano F
    J Virol; 2005 Jan; 79(1):234-44. PubMed ID: 15596819
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Systems to establish bunyavirus genome replication in the absence of transcription.
    Klemm C; Reguera J; Cusack S; Zielecki F; Kochs G; Weber F
    J Virol; 2013 Jul; 87(14):8205-12. PubMed ID: 23698297
    [TBL] [Abstract][Full Text] [Related]  

  • 48. SAR analysis of a series of acylthiourea derivatives possessing broad-spectrum antiviral activity.
    Burgeson JR; Moore AL; Boutilier JK; Cerruti NR; Gharaibeh DN; Lovejoy CE; Amberg SM; Hruby DE; Tyavanagimatt SR; Allen RD; Dai D
    Bioorg Med Chem Lett; 2012 Jul; 22(13):4263-72. PubMed ID: 22664128
    [TBL] [Abstract][Full Text] [Related]  

  • 49. La Crosse and other forms of California encephalitis.
    Rust RS; Thompson WH; Matthews CG; Beaty BJ; Chun RW
    J Child Neurol; 1999 Jan; 14(1):1-14. PubMed ID: 10025535
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Metal coordinating inhibitors of Rift Valley fever virus replication.
    Geerling E; Murphy V; Mai MC; Stone ET; Casals AG; Hassert M; O'Dea AT; Cao F; Donlin MJ; Elagawany M; Elgendy B; Pardali V; Giannakopoulou E; Zoidis G; Schiavone DV; Berkowitz AJ; Agyemang NB; Murelli RP; Tavis JE; Pinto AK; Brien JD
    PLoS One; 2022; 17(9):e0274266. PubMed ID: 36112605
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antivirally active MxA protein sequesters La Crosse virus nucleocapsid protein into perinuclear complexes.
    Kochs G; Janzen C; Hohenberg H; Haller O
    Proc Natl Acad Sci U S A; 2002 Mar; 99(5):3153-8. PubMed ID: 11880649
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Investigation of Acute Flaccid Paralysis Reported with La Crosse Virus Infection, Ohio, USA, 2008-2014.
    Hennessey MJ; Pastula DM; Machesky K; Fischer M; Lindsey NP; DiOrio M; Staples JE; de Fijter S
    Emerg Infect Dis; 2017 Dec; 23(12):2075-2077. PubMed ID: 29148398
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Modulation of La Crosse Virus Infection in Aedes albopictus Mosquitoes Following Larval Exposure to Coffee Extracts.
    Eastep NE; Albert RE; Anderson JR
    Front Physiol; 2012; 3():66. PubMed ID: 22470349
    [TBL] [Abstract][Full Text] [Related]  

  • 54. La Crosse virus neuroinvasive disease: the kids are not alright.
    Day CA; Byrd BD; Trout Fryxell RT
    J Med Entomol; 2023 Nov; 60(6):1165-1182. PubMed ID: 37862102
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Serological survey and active surveillance for La Crosse virus infections among children in Tennessee.
    Jones TF; Erwin PC; Craig AS; Baker P; Touhey KE; Patterson LE; Schaffner W
    Clin Infect Dis; 2000 Nov; 31(5):1284-7. PubMed ID: 11073765
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Geographically persistent clusters of La Crosse virus disease in the Appalachian region of the United States from 2003 to 2021.
    Day CA; Odoi A; Trout Fryxell R
    PLoS Negl Trop Dis; 2023 Jan; 17(1):e0011065. PubMed ID: 36656896
    [TBL] [Abstract][Full Text] [Related]  

  • 57. La Crosse Virus Field Detection and Vector Competence of Culex Mosquitoes.
    Harris MC; Yang F; Jackson DM; Dotseth EJ; Paulson SL; Hawley DM
    Am J Trop Med Hyg; 2015 Sep; 93(3):461-7. PubMed ID: 26175029
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neuronal maturation reduces the type I IFN response to orthobunyavirus infection and leads to increased apoptosis of human neurons.
    Winkler CW; Woods TA; Groveman BR; Carmody AB; Speranza EE; Martens CA; Best SM; Haigh CL; Peterson KE
    J Neuroinflammation; 2019 Nov; 16(1):229. PubMed ID: 31739796
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Narasin, a novel antiviral compound that blocks dengue virus protein expression.
    Low JS; Wu KX; Chen KC; Ng MM; Chu JJ
    Antivir Ther; 2011; 16(8):1203-18. PubMed ID: 22155902
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Differences in Neuropathogenesis of Encephalitic California Serogroup Viruses.
    Evans AB; Winkler CW; Peterson KE
    Emerg Infect Dis; 2019 Apr; 25(4):728-738. PubMed ID: 30882310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.